Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Wall Street
Price Targets
Price Targets Summary
Shanghai RAAS Blood Products Co Ltd
According to Wall Street analysts, the average 1-year price target for Shanghai RAAS Blood Products Co Ltd is 9 CNY .
Price Targets
Revenue
Forecast
Revenue Estimate
Shanghai RAAS Blood Products Co Ltd
For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's revenue is 22%. The projected CAGR for the next 3 years is 17%.
Operating Income
Forecast
Operating Income Estimate
Shanghai RAAS Blood Products Co Ltd
For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's operating income is 17%. The projected CAGR for the next 3 years is 25%.
Net Income
Forecast
Net Income Estimate
Shanghai RAAS Blood Products Co Ltd
For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's net income is 18%. The projected CAGR for the next 3 years is 18%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is Shanghai RAAS Blood Products Co Ltd's stock price target?
Price Target
9
CNY
According to Wall Street analysts, the average 1-year price target for Shanghai RAAS Blood Products Co Ltd is 9 CNY .
What is Shanghai RAAS Blood Products Co Ltd's Revenue forecast?
Projected CAGR
17%
For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's revenue is 22%. The projected CAGR for the next 3 years is 17%.
What is Shanghai RAAS Blood Products Co Ltd's Operating Income forecast?
Projected CAGR
25%
For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's operating income is 17%. The projected CAGR for the next 3 years is 25%.
What is Shanghai RAAS Blood Products Co Ltd's Net Income forecast?
Projected CAGR
18%
For the last 8 years the compound annual growth rate for Shanghai RAAS Blood Products Co Ltd's net income is 18%. The projected CAGR for the next 3 years is 18%.